JP Morgan Chase’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-2,317
| Closed | -$13K | – | 7765 |
|
|
2024
Q2 | $13K | Sell |
2,317
-56,314
| -96% | -$245K | ﹤0.01% | 6215 |
|
|
2024
Q1 | $307K | Sell |
58,631
-2,936
| -5% | -$16.1K | ﹤0.01% | 5091 |
|
|
2023
Q4 | $322K | Sell |
61,567
-1,577
| -2% | -$15.6K | ﹤0.01% | 5058 |
|
|
2023
Q3 | $996K | Sell |
63,144
-55,064
| -47% | -$989K | ﹤0.01% | 4065 |
|
|
2023
Q2 | $2.3M | Sell |
118,208
-11,855
| -9% | -$281K | ﹤0.01% | 3438 |
|
|
2023
Q1 | $3.69M | Buy |
130,063
+18,648
| +17% | +$554K | ﹤0.01% | 3055 |
|
|
2022
Q4 | $3.26M | Sell |
111,415
-120,391
| -52% | -$3.83M | ﹤0.01% | 3178 |
|
|
2022
Q3 | $6.13M | Buy |
231,806
+26,959
| +13% | +$989K | ﹤0.01% | 2565 |
|
|
2022
Q2 | $9.1M | Sell |
204,847
-33,892
| -14% | -$1.56M | ﹤0.01% | 2248 |
|
|
2022
Q1 | $11.8M | Sell |
238,739
-5,007
| -2% | -$240K | ﹤0.01% | 2201 |
|
|
2021
Q4 | $12.4M | Sell |
243,746
-87,552
| -26% | -$4.54M | ﹤0.01% | 2261 |
|
|
2021
Q3 | $18.5M | Sell |
331,298
-14,177
| -4% | -$698K | ﹤0.01% | 1833 |
|
|
2021
Q2 | $14.8M | Buy |
345,475
+276,753
| +403% | +$11.4M | ﹤0.01% | 2085 |
|
|
2021
Q1 | $2.87M | Sell |
68,722
-6,813
| -9% | -$316K | ﹤0.01% | 3426 |
|
|
2020
Q4 | $3.52M | Buy |
75,535
+12,662
| +20% | +$592K | ﹤0.01% | 3079 |
|
|
2020
Q3 | $2.63M | Sell |
62,873
-1,618
| -3% | -$70.8K | ﹤0.01% | 3042 |
|
|
2020
Q2 | $3.09M | Sell |
64,491
-3,903
| -6% | -$195K | ﹤0.01% | 2812 |
|
|
2020
Q1 | $3.15M | Sell |
68,394
-7,875
| -10% | -$395K | ﹤0.01% | 2623 |
|
|
2019
Q4 | $4.58M | Sell |
76,269
-3,733
| -5% | -$223K | ﹤0.01% | 2755 |
|
|
2019
Q3 | $4.53M | Sell |
80,002
-18,686
| -19% | -$1.05M | ﹤0.01% | 2772 |
|
|
2019
Q2 | $5.43M | Sell |
98,688
-6,211
| -6% | -$324K | ﹤0.01% | 2570 |
|
|
2019
Q1 | $5.3M | Buy |
104,899
+45,821
| +78% | +$2.04M | ﹤0.01% | 2542 |
|
|
2018
Q4 | $2.38M | Sell |
59,078
-4,426
| -7% | -$228K | ﹤0.01% | 3156 |
|
|
2018
Q3 | $4.4M | Buy |
63,504
+29,215
| +85% | +$2.21M | ﹤0.01% | 2840 |
|
|
2018
Q2 | $2.6M | Buy |
34,289
+31,929
| +1,353% | +$2.01M | ﹤0.01% | 3202 |
|
|
2018
Q1 | $124K | Sell |
2,360
-14
| -0.6% | -$814 | ﹤0.01% | 4525 |
|
|
2017
Q4 | $127K | Buy |
2,374
+1,915
| +417% | +$107K | ﹤0.01% | 4576 |
|
|
2017
Q3 | $27K | Buy |
+459
| New | +$27.8K | ﹤0.01% | 4591 |
|
|
2016
Q3 | – | Sell |
-124
| Closed | -$5K | – | 4866 |
|
|
2016
Q2 | $5K | Buy |
124
+35
| +39% | +$1.46K | ﹤0.01% | 4464 |
|
|
2016
Q1 | $4K | Buy |
89
+79
| +790% | +$5.01K | ﹤0.01% | 4413 |
|
|
2015
Q4 | $1K | Buy |
+10
| New | +$790 | ﹤0.01% | 4626 |
|
|
2015
Q2 | – | Sell |
-6,630
| Closed | -$278K | – | 4220 |
|
|
2015
Q1 | $278K | Buy |
+6,630
| New | +$188K | ﹤0.01% | 3733 |
|
|
2014
Q2 | – | Sell |
-177,650
| Closed | -$2.27M | – | 3642 |
|
|
2014
Q1 | $2.27M | Buy |
+177,650
| New | +$2.41M | ﹤0.01% | 2494 |
|
Other funds holding EGRX
NCM
ACM
JP Morgan Chase's EGRX Position: Q3 2024 in Review
JP Morgan Chase sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 2,317 shares — an estimated $13K sold.
JP Morgan Chase first reported a position in EGRX in Q1 2014 and held it in 33 quarters. The position peaked at $18.5M in Q3 2021. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.
- JP Morgan Chase reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
- JP Morgan Chase sold 2,317 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $13K.
- JP Morgan Chase first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 33 quarters.
- JP Morgan Chase's Eagle Pharmaceuticals, Inc. position peaked at $18.5M in Q3 2021.
- 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.
Based on JP Morgan Chase's 13F filing for Q3 2024, filed 8 Nov 2024.